The study of the efficacy of a second line Luteinizing hormone-releasing hormone agonist after prostate cancer biochemical recurrence

The study of the efficacy of a second line Luteinizing hormone-releasing hormone agonist after prostate cancer biochemical recurrence - The study of the efficacy of a second line Luteinizing hormone-releasing hormone agonist after prostate cancer biochemical recurrence

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011255

Enrollment

Registered

2013-07-23

Start date

2012-10-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with prostate cancer who received luteinizing hormone-releasing hormone (LH-RH) agonist, had biochemical progression

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Patient with prostate cancer defined by pathological examination 2. Patient with first biochemical failure during hormone therapy 3. Patient age above 20 years or older 4. Performance status grade 0, 1 or 2 5. Chemical laboratory values met predefined criteria

Exclusion criteria

Exclusion criteria: 1. Serum teststerone level above 0.5ng/ml 2. Patient with clinical symptom, bone pain or urinary retention at PSA failure 3. Patient with the treatment history, who was administered both goserelin and leuprolide 4. Patient administered anti-androgen drug as CAB 5. Administeration of estrogen 6. Sytemic administeration of corticosteroid 7. Patient received chemotherapy 8. Patient with severe diabetes 9. Patients with severe psychosis 10. Patients with double cancer

Design outcomes

Primary

Measure	Time frame
The percent prostate specific antigen change after switching luteinizing hormone-releasing hormone agonist therapy at 3 and 6 months	—

Countries

Japan

Contacts

Public ContactYoshiyuki Miyaji

Kawasaki Medical School Department of Urology

miyaji@med.kawasaki-m.ac.jp086-462-1111

Outcome results